Health Discovery Corporation (OTCBB: HDVY) announced today that it delivered a letter of gratitude and support to Congressman Edolphus Towns, Chairman of the House Committee on Oversight and Government Reform for holding today, March 4, 2010, a congressional hearing on “Prostate Cancer: New Questions About Screening and Treatment.”

“Congressman Towns’ public hearing is timely and appropriate, given the overwhelming data about the failures of the PSA for detecting clinically significant prostate cancer,” said Stephen D. Barnhill, Chairman and CEO of Health Discovery Corporation. “Given our pioneering work in molecular diagnostic testing for prostate cancer, Health Discovery Corporation naturally offered to Congressman Towns our gratitude, support and ourselves as a resource to him and his committee as he continues to explore this important issue,” said Dr. Barnhill.

The full text of the letter is as follows:

March 4, 2010

The Honorable Edolphus Towns, ChairmanHouse Committee on Oversight and Government Reform2157 Rayburn House Office BuildingWashington, DC 20515

Dear Chairman Towns,

Thank you for your leadership on promoting awareness and research about prostate cancer. Indeed, it is our hope that your hearing, Prostate Cancer: New Questions About Screening and Treatment, will raise the level of understanding about prostate cancer among members and generate the kind of detailed examination that will help us advance research for testing and treatment for this terrible disease. As you well know, there is an estimated 192,280 new cases of prostate cancer in 2009 and some 27,360 deaths from the disease.

Health Discovery Corporation’s new 4-gene molecular diagnostic test for prostate cancer has been shown to have a 90% Sensitivity (for finding clinically significant grade 3 or higher prostate cancer cells) and a 97% Specificity (for finding non-cancerous cells) was recently published in the peer-reviewed publication, UroToday International (August 2009).

Health Discovery Corporation (HDC) shares your commitment to exploring solutions to prostate cancer. Indeed, HDC is a pioneer in developing sophisticated pattern recognition technology called “Support Vector Machine” (SVM) and has developed, and continues to develop, effective molecular diagnostic tests for cancer. Currently, we have 42 issued patents and 32 pending patents involving SVM technology.

SVM technology has been shown in numerous peer-reviewed publications from some of the top academic institutions in the world to be a superior pattern recognition tool for molecular diagnostic/prognostic test development. By analyzing vast amounts of data (including genomic, proteomic, and clinical data on patients, as well as, image analysis data from both digital pathology and radiology), HDC can develop objective and accurate tests for use in personalized medicine. Personalized medicine identifies the correct treatment, for the correct patient, in the correct dose.

Of particular interest to you may be our new partnership with the Pancreas, Biliary and Liver Surgery Center of New York (the “Center”) to develop new molecular diagnostic tests for the early detection of pancreatic cancer. The Center is providing HDC with colon specimens that will facilitate the final validation study for our colon cancer test. As you may well know, the Center is affiliated with Beth Israel Hospital, New York Downtown Hospital, St. John's Hospital, Lenox Hill Hospital, St. Vincent’s Hospital and Mt. Sinai Medical Center.

Again, Mr. Chairman, thank you for your leadership on this issue. We look forward to reviewing the results of the hearing today and offer ourselves as a resource to you and your committee as you continue to explore this important issue.

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.

Copyright Business Wire 2010